Assessment of a novel intra-prostate sustained release docetaxel combined with radiation treatment of prostate cancer: a canine BPH Model

BACKGROUND: Prostate cancer treatment commonly involves chemotherapy, radiation, and surgery, but systemic administration of cytotoxic agents is limited by dose-limiting toxicities. Localized delivery strategies may overcome these limitations. We evaluated the feasibility of a novel intra-prostatic docetaxel sustained-release implant (InCeRT-DTX) combined with external beam radiation therapy (EBRT) in a large animal model. METHODS: Nineteen beagle dogs with benign prostatic hyperplasia (BPH) received surgical implantation of InCeRT-DTX into the prostate. A subset also underwent a single 16 Gy dose of EBRT. Pharmacokinetics, safety, local toxicity, and therapeutic responses were assessed by serum analysis, imaging, and histopathology. RESULTS: The tolerated intra-prostatic docetaxel dose was 9 µg per cm³ of prostate volume-over 10-fold higher than the estimated dose achievable by intravenous delivery in humans. At this dose, no systemic toxicities were observed, and local effects were minimal and non-clinical. Implants alone produced negligible changes in prostate morphology; however, the combination of InCeRT-DTX with EBRT resulted in a 38-45% reduction in prostate volume. Histopathological analysis showed limited necrosis and fibrosis localized to the implant site, while increased apoptotic activity suggested apoptosis as a primary mechanism of glandular shrinkage. CONCLUSIONS: Localized delivery of docetaxel via InCeRT-DTX implants enables safe administration of high intra-prostatic doses without systemic toxicity. When combined with EBRT, this approach produces significant prostate volume reduction, indicating a synergistic therapeutic effect. These findings support the translational potential of "inside-out" chemotherapy as a novel prostate cancer treatment strategy.

Authors

Institutions

Publication Details

Journal
Prostate Cancer and Prostatic Diseases
Published
2026-11-20
DOI
https://doi.org/10.1038/s41391-026-01174-9
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Assessment of a novel intra-prostate sustained release docetaxel combined with radiation treatment of prostate cancer: a canine BPH Model

Alireza Kheirollah, Dylan B. Ness, Lionel D. Lewis, David J. Gladstone et al.
Prostate Cancer and Prostatic Diseases
Prostate Cancer Diagnosis and Treatment
article

Assessment of a novel intra-prostate sustained release docetaxel combined with radiation treatment of prostate cancer: a canine BPH Model

Alireza Kheirollah, Dylan B. Ness, Lionel D. Lewis, David J. Gladstone, Robert A. Cormack, Srinivas Sridhar, Shicheng Yang, G. Mike Makrigiorgos, Anthony V. D’Amico, Armin D. Tavakkoli, Paul L. Nguyen, P. Jack Hoopes, Gretchen Carpenter
article en

Abstract

BACKGROUND: Prostate cancer treatment commonly involves chemotherapy, radiation, and surgery, but systemic administration of cytotoxic agents is limited by dose-limiting toxicities. Localized delivery strategies may overcome these limitations. We evaluated the feasibility of a novel intra-prostatic docetaxel sustained-release implant (InCeRT-DTX) combined with external beam radiation therapy (EBRT) in a large animal model. METHODS: Nineteen beagle dogs with benign prostatic hyperplasia (BPH) received surgical implantation of InCeRT-DTX into the prostate. A subset also underwent a single 16 Gy dose of EBRT. Pharmacokinetics, safety, local toxicity, and therapeutic responses were assessed by serum analysis, imaging, and histopathology. RESULTS: The tolerated intra-prostatic docetaxel dose was 9 µg per cm³ of prostate volume-over 10-fold higher than the estimated dose achievable by intravenous delivery in humans. At this dose, no systemic toxicities were observed, and local effects were minimal and non-clinical. Implants alone produced negligible changes in prostate morphology; however, the combination of InCeRT-DTX with EBRT resulted in a 38-45% reduction in prostate volume. Histopathological analysis showed limited necrosis and fibrosis localized to the implant site, while increased apoptotic activity suggested apoptosis as a primary mechanism of glandular shrinkage. CONCLUSIONS: Localized delivery of docetaxel via InCeRT-DTX implants enables safe administration of high intra-prostatic doses without systemic toxicity. When combined with EBRT, this approach produces significant prostate volume reduction, indicating a synergistic therapeutic effect. These findings support the translational potential of "inside-out" chemotherapy as a novel prostate cancer treatment strategy.

Prostate Cancer and Prostatic Diseases
Dartmouth College (US), Brigham and Women's Hospital (US), Dartmouth–Hitchcock Medical Center (US), Northeastern University (US), Dana-Farber Cancer Institute (US), Dartmouth Psychiatric Research Center (US), Dana-Farber Brigham Cancer Center (US), Dartmouth Cancer Center (US)
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon